AKBA - CIK 0001517022
The table below shows Akebia Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $162.64M | $166.44M | $137.31M | $113.37M | $34.02M | $39.50M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $62.54M | $66.22M | $72.81M | $61.54M | $32.17M | $29.77M |
| Inventory | $13.00M | $18.64M | $16.71M | $19.73M | $20.49M | $23.87M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $243.48M |
| $258.34M |
| $234.66M |
| $203.78M |
| $100.12M |
| $112.10M |
| Property, plant & equipment | $956.00K | $1.47M | $1.71M | $1.90M | $2.53M | $2.90M |
| Goodwill | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M | $59.04M |
| Total assets | $362.52M | $364.15M | $345.60M | $310.19M | $207.14M | $220.20M |
| Accounts payable | $8.39M | $10.09M | $11.55M | $12.66M | $13.49M | $10.11M |
| Total current liabilities | $173.88M | $133.38M | $118.72M | $91.23M | $65.71M | $107.30M |
| Long-term debt | $36.40M | $47.64M | $47.06M | $46.51M | $38.35M | $38.03M |
| Total liabilities | $335.14M | $322.56M | $316.37M | $285.60M | $257.54M | $253.95M |
| Retained earnings | -$1.69B | -$1.67B | -$1.67B | -$1.67B | -$1.66B | -$1.64B |
| Total equity | $27.38M | $41.59M | $29.22M | $24.58M | -$50.40M | -$33.75M |